Open an account

Trevi Therapeutics

TRVI · NASDAQ

$12.83+$0.93 (+7.82%)TodayMarket closed ·
Prev close $11.90

About TRVI

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 34 full-time employees. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. The company has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Employees
34
Headquarters
New Haven, Connecticut
Listed
May 7, 2019
Sector
Health Care
Industry
Pharmaceuticals
Website
trevitherapeutics.com

TRVI key statistics

Market cap
1.70B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.81M
Volume
1.39M
Open price
$12.11
High today
$13.11
Low today
$11.93
52 Week high
$20.22
52 Week low
$9.82

Trevi Therapeutics (TRVI) at a glance

Trevi Therapeutics (TRVI) last traded at $12.83, with a market cap of 1.70B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.93 and $13.11. The current price is 7.5% above the day's low and 2.1% below its high.

Volume so far is 1.39M shares, below the average of 2.81M shares a day.

Over the past year Trevi Therapeutics has ranged from $9.82 to $20.22, and now sits 29% of the way up that range.

Trevi Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.11 per share against an estimate of -$0.1125.

The average analyst price target is $30.09, 134.5% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 12 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 14 analystsAvg $30.09
Low
$23.23
Now
$12.83
High
$42.00

TRVI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 18.6% on average.

  1. Q3 FY24: reported -$0.13 per share against an estimate of -$0.1208
  2. Q4 FY24: reported -$0.11 per share against an estimate of -$0.1213
  3. Q1 FY25: reported -$0.09 per share against an estimate of -$0.1235
  4. Q2 FY25: reported -$0.09 per share against an estimate of -$0.103
  5. Q3 FY25: reported -$0.08 per share against an estimate of -$0.1003
  6. Q4 FY25: reported -$0.06 per share against an estimate of -$0.1001
  7. Q1 FY26: reported -$0.09 per share against an estimate of -$0.078
  8. Q2 FY26: reported -$0.11 per share against an estimate of -$0.1125

TRVI news

  • Trevi Therapeutics Q2 2026 Earnings Call Transcript

  • Press releaseGlobe Newswire

    Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

  • Press releaseGlobe Newswire

    Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026

  • Press releaseGlobe Newswire

    Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

  • Press releasePRNewswire

    Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

Similar companies

Companies in the same industry as Trevi Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.